Metformin use and mortality and length of stay among hospitalized patients with type 2 diabetes and COVID-19: A multiracial, multiethnic, urban observational study
Emily Miao, Kaleena Zhang, Jianyou Liu, Juan Lin, Donna Yoo, Claudene J George
Frontiers in Endocrinology, doi:10.3389/fendo.2022.1002834
Introduction: Diabetes mellitus is a common comorbidity among patients with coronavirus disease 2019 . Diabetic patients with COVID-19 have a two-fold increased risk of death and tend to have more severe infection compared to the general population. Metformin, a first-line medication for diabetes management, has anti-inflammatory and immunomodulatory effects. Previous studies focusing on metformin and COVID-19 clinical outcomes have had mixed results, with some showing a mortality benefit or decreased complications with metformin use. To date, few studies have analyzed such outcomes among a diverse, multiracial community. Methods: This was a retrospective review of patients with Type 2 diabetes and a confirmed COVID-19 infection admitted to an urban academic medical center from January 1, 2020 to May 7, 2020. Baseline characteristics were collected. The primary outcomes of the study were in-hospital mortality and length of stay (LOS). Results: A total of 4462 patients with Type 2 diabetes and confirmed COVID-19 were identified. 41.3% were Black, and 41.5% were Hispanic. There were 1021 patients in the metformin group and 3441 in the non-metformin group. Of note, more participants in the metformin group had comorbid disease and/or advanced diabetes. We found no statistically significant differences between the metformin and non-metformin group in in-hospital mortality (28.1% vs 25.3%, P=0.08) or length of hospital stay in days (7.3 vs. 7.5, P=0.59), even after matching patients on various factors (29.3% vs. 29.6%, P=0.87; 7.7 vs. 8.1, P=0.23).
Ethics statement The studies involving human participants were reviewed and approved by Albert Einstein College of Medicine, Montefiore Medical Center Institutional Review Board. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.
Author contributions EM: Design, data management, interpretation of data, and preparation of manuscript; KZ: Design, data management, interpretation of data, and preparation of manuscript; JiL: Data management, analysis, interpretation of data, preparation of manuscript; JuL: Data management, analysis, interpretation of data, preparation of manuscript; DY: Interpretation of data, preparation of manuscript; CG: Design, acquisition of subjects, data management, analysis, interpretation of data, preparation of manuscript. All authors contributed to the article and approved the submitted version.
Conflict of interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's note All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Apicella, Campopiano, Mantuano, Mazoni, Coppelli et al., COVID-19 in people with diabetes: understanding the reasons for worse outcomes, Lancet Diabetes Endocrinol,
doi:10.1016/S2213-8587(20)30238-2Chen, Yang, Cheng, Chen, Peng et al., Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication, Diabetes Care,
doi:10.2337/dc20-0660Crouse, Grimes, Li, Might, Ovalle et al., Metformin use is associated with reduced mortality in a diverse population with COVID-19 and diabetes, Front Endocrinol,
doi:10.3389/fendo.2020.600439Ejaz, Alsrhani, Zafar, Javed, Junaid et al., COVID-19 and comorbidities: Deleterious impact on infected patients, J Infect Public Health,
doi:10.1016/j.jiph.2020.07.014Gao, Liu, Zhong, Liu, Zhou et al., Risk of metformin in patients with type 2 diabetes with COVID-19: A preliminary retrospective report, Clin Transl Sci,
doi:10.1111/cts.12897Gaskin, Mcginty, Bower, Rohde, Young, Disparities in diabetes: the nexus of race, poverty, and place, Am J Public Health,
doi:10.2105/AJPH.2013.301420Guo, Li, Dong, Zhou, Zhang et al., Diabetes is a risk factor for the progression and prognosis of COVID-19, Diabetes Metab Res Rev,
doi:10.1002/dmrr.3319Heald, Jenkins, Williams, Sperrin, Mudaliar et al., Mortality in people with type 2 diabetes following SARS-CoV-2 infection: A population level analysis of potential risk factors, Diabetes Ther
Hou, Li, Zhang, Wu, Shi et al., Smoking is independently associated with an increased risk for COVID-19 mortality: A systematic review and meta-analaysis based on adjusted effect estimates, Nicotine Tob Res,
doi:10.1093/ntr/ntab112Jiang, Chen, Liu, Yin, Yang et al., Association of metformin with mortality or ARDS in patients with COVID-19 and type 2 diabetes: A retrospective cohort study, Diabetes Res Clin Pract,
doi:10.1016/j.diabres.2020.108619Lalau, Al-Salameh, Hadjadj, Goronflot, Wiernsperger et al., Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19, Diabetes Metab,
doi:10.1016/j.diabet.2020.101216Lim, Bae, Kwon, Nauck, COVID-19 and diabetes mellitus: from pathophysiology to clinical management, Nat Rev Endocrinol,
doi:10.1038/s41574-020-00435-4Luo, Qiu, Liu, Liu, Zheng et al., Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis, Am J Trop Med Hyg,
doi:10.4269/ajtmh.20-0375Mackey, Ayers, Kondo, Saha, Advani et al., Racial and ethnic disparities in COVID-19-Related infections, hospitalizations, and deaths : A systematic review, Ann Intern Med,
doi:10.7326/M20-6306Oh, Song, Prior metformin therapy and 30-day mortality in patients with acute respiratory distress syndrome: a nationwide cohort study, Ann Palliative Med,
doi:10.21037/apm.2020.04.25Reis, Silva, Silva, Thabane, Milagres et al., Effect of early treatment with metformin on risk of emergency care and hospitalization among patients with COVID-19: The TOGETHER randomized platform clinical trial, Lancet Regional Health -Americas,
doi:10.1016/j.lana.2021.100142Singh, Singh, Saboo, Misra, Zangiabadian et al., The efficacy and potential mechanisms of metformin in the treatment of COVID-19 in the diabetics: A systematic review, Diabetes Metab Syndr,
doi:10.3389/fendo.2021.645194Yang, Sun, Zhang, Zhang, The effect of metformin on mortality and severity in COVID-19 patients with diabetes mellitus, Diabetes Res Clin Pract,
doi:10.1016/j.diabres.2021.108977Zhu, She, Cheng, Qin, Zhang et al., Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes, Lancet Healthy Longevity,
doi:10.1016/S2666-7568(20)30033-7
